Search results
He co-invented EP-2104R, which was the first molecularly targeted MRI contrast agent to enter clinical trials, and RVP-001, a manganese-based general purpose MRI contrast agent currently in clinical development. Since joining MGH in 2007, he has been continuously funded by the NIH.
Following postdoctoral work at the EPFL (Switzerland), he spent 9 years at Epix Pharmaceuticals developing tissue-specific and responsive MRI contrast agents, one of which, gadofosveset, was approved by the FDA and the EMA.
People also ask
Who is Dr caravan?
Where did Dr caravan get his PhD?
How many research papers has Dr Caravan published?
Who is Peter Caravan?
Peter Caravan. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging (i3), MGH, Harvard. Verified email at nmr.mgh.harvard.edu. Chemistry PET MRI Thrombosis Fibrosis.
Sep 11, 2023 · Dr. Caravan has published over 200 peer-reviewed articles, is a named inventor on over 25 issued patents, has brought multiple PET and MRI probes to first-in-human studies, and has co-founded two companies.
Peter Caravan's 303 research works with 18,055 citations and 7,668 reads, including: Simultaneous PET and molecular MR imaging of cardiopulmonary fibrosis in a mouse model of left...
Feb 1, 2022 · Dr. Caravan received a PhD in Inorganic Chemistry from the University of British Columbia. Following postdoctoral work at the EPFL (Switzerland), he spent 9 years at Epix Pharmaceuticals developing tissue-specific and responsive MRI contrast agents, one of which, gadofosveset, was approved by the FDA and the EMA.
